Qiagen (NASDAQ:QGEN) Earns Daily News Impact Score of 0.11
Media stories about Qiagen (NASDAQ:QGEN) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Qiagen earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.0675594242178 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Global Bioinformatics Market 2018 Key Players: QIAGEN NV, Agilent Technologies, Thermo Fisher Scientific , Affymetrix (dailybizreport.com)
- Global Electrophoresis Reagents Market Growth (2018 – 2023): Sigma-Aldrich Corporation (US), QIAGEN NV … (firstpharmacist.com)
- Stock Spotlight: QIAGEN NV (QGEN), Banco Santander-Chile (BSAC) (247trendingnews.website)
- Global Cervical Dysplasia Market 2018 – Hologic, Inc, QIAGEN NV, Quest Diagnostics (hitmarketresearch.com)
- Global Whole Genome Amplification Market by Companies: Sigma-Aldrich, QIAGEN NV, GE Healthcare, LGC Group … (tvaccent.com)
Shares of NASDAQ QGEN traded down $0.72 during mid-day trading on Friday, reaching $37.51. 891,878 shares of the company’s stock traded hands, compared to its average volume of 957,862. Qiagen has a 1-year low of $30.20 and a 1-year high of $39.45. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.
Several equities analysts recently commented on QGEN shares. TheStreet raised shares of Qiagen from a “c+” rating to a “b” rating in a research note on Friday, May 25th. Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a research note on Friday, August 3rd. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research note on Wednesday, July 25th. Barclays reissued a “buy” rating and set a $43.00 target price on shares of Qiagen in a research note on Thursday, September 6th. Finally, Zacks Investment Research raised shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $38.33.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
See Also: Do Tariffs Work?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.